Livewire Ergogenics Inc (LVVV): Well I can’t prove bill personally payed...

Well I can’t prove bill personally payed or

weekend farmer · 2025-02-20T00:47:18.9900000Z

Well I can’t prove bill personally payed or didn’t pay the taxes . I did find some interesting information here on the matter https://crrecords.slocounty.ca.gov/SLOWeb/search/DOCSEARCH262S3 Estrella Ranch partners LLC Estrella land company LLC All names if one needs to search

Play Episode

11min

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Nexus Minerals expands Payns Find gold target

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Followers	36
Posts	3551
Boards Moderated	0
Alias Born	06/03/2009

Volume:	10,250,500
Day Range:	0.00055 - 0.0006
Bid:	0.0005
Ask:	0.0007
Last Trade Time:	3:14:48 PM EDT
Total Trades:	28

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

LVVV Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free